U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Go back to U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 13.47 +0.02 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.45 | 52 Week High | $19.40 | |||
| Open | $13.48 | 52 Week Low | $12.50 | |||
| Day High | $13.56 | P/E | N/A | |||
| Day Low | $13.45 | EPS | $0.00 | |||
| Volume | 174,991 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 25.07 -0.14 (0.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.21 | 52 Week High | $37.39 | |||
| Open | $25.22 | 52 Week Low | $28.25 | |||
| Day High | $25.31 | P/E | 15.19 | |||
| Day Low | $24.96 | EPS | $1.65 | |||
| Volume | 16,542,524 | |||||
